ReviewJournal of diabetes science and technology2025
Optimizing Type 1 Diabetes Screening in People With Family History: A German Perspective.
Review in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with a family history of type 1 diabetes (T1D) are at significantly higher risk of developing T1D compared to the general population. Before its clinical onset, individuals with T1D can be identified through islet autoantibody (IAb) testing which, if multiple IAbs are detected, justifies the diagnosis of early-stage T1D. Amid rising global T1D incidence, we outline Germany's strategy for early detection and management focused on individuals with a family history and, where informative, implementation lessons are illustrated using findings from the German Fr1da general-population study. Genetic risk factors for T1D development in individuals with family history are discussed, as well as impacts of positive screening results including influence on diabetic ketoacidosis (DKA) rates and psychological aspects. In parallel, recommendations and consensus guidelines from other national screening efforts are introduced. Building on this, we address challenges in nationwide T1D family-based screening integration and explore leveraging health care systems for cost-effective implementation. We also provide practical aspects to overcome barriers for family-based T1D screening and introduce monitoring strategies in individuals with early-stage T1D. With the advent of disease-modifying therapies (DMTs) for delaying T1D progression, there is now a rationale at hand that offers an IAb screening incentive. Collectively, we emphasize the critical role of early detection and monitoring among at-risk relatives in mitigating the burden of T1D on individuals, families, and health care systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.